Basic information
- CAS
167305-00-2- Standard SMILES
O=C(N[C@H]1CCS[C@H]2CCC[C@@H](C(=O)O)N2C1=O)[C@@H](S)Cc1ccccc1- InChIKey
LVRLSYPNFFBYCZ-VGWMRTNUSA-N- Molecular formula
- C19H24N2O4S2
- Average molar mass
- 408.5 g/mol
- Monoisotopic mass
- 408.1177496
Overview
Omapatrilat is a dipeptide.
Names & identifiers
- Preferred name
- Omapatrilat
- IUPAC
- (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
- English name
- OMAPATRILAT
- Molecular formula
- C19H24N2O4S2
- Molecular weight
- 408.53
Names & synonyms
Omapatrilat167305-00-2BMS-186716VanlevOmapatrilateBMS-186716-0136NLI90E7TDTXSID80168273(4S,7S,10aS)-Octahydro-4-((S)-alpha-mercaptohydrocinnamamido)-5-oxo-7H-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acidoctahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo-7H-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acidomapatrilatum(4S,7S,10aS)-Octahydro-4-[(S)-alpha-mercaptohydrocinnamamido]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
Show more names
BMS 186716-01OMAPATRILAT/VANLEVOmapatrilat (BMS-186716)Omapatrilat >=98% (HPLC)7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-, (4S,7S,10aS)-
RefChem:856761DTXCID4090764(4S,7S,10aS)-5-oxo-4-((2S)-3-phenyl-2-sulfanylpropanamido)-octahydro-2H-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acidBms 186716(4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acidCHEMBL289556(4S,7S,10aS)-4-((S)-2-mercapto-3-phenylpropanamido)-5-oxooctahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid(4S,7S,10aS)-4-((S)-2-Mercapto-3-phenylpropanamido)-5-oxooctahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
Database identifiers
- CAS
167305-00-2- PubChem CID
- 656629
- DTXSID
DTXSID80168273- ChEMBL
CHEMBL289556- ChEBI
CHEBI:135660- UNII
- 36NLI90E7T
- EC Number
- 110-388-4
- Nikkaji
- J851.014H
Properties
Computed structural properties
- XLogP
- 2.8
- Topological polar surface area
- 113 Ų
- Hydrogen bond donors
- 3
- Hydrogen bond acceptors
- 6
- Rotatable bonds
- 5
- Heavy atoms
- 27
- Formal charge
- 0
- Complexity
- 568
Experimental & physicochemical properties
DrugsPharmaceuticals -> Listed in ZINC15
Physicochemical properties
- Melting point
- 218 · 218-220°
- alpha
- -78.9 ° · D -78.9° (c = 0.46 in DMF)
- Boiling point
- 724.2 · 724.2±60.0 °C(Predicted)
- Density
- 1.37 · 1.37±0.1 g/cm3(Predicted)
- storage temp.
- 2 · under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- 30 mg/ml · DMSO: 30 mg/ml
- form
- A crystalline solid
- pka
- 3.44 · 3.44±0.40(Predicted)
- color
- White to gray
- FDA UNII
- 36 NLI90E7T · 36NLI90E7T
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302-H315-H319-H335
- Precautionary statements
- 261 · P261-P305+P351+P338
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Hazard Classes and CategoriesSkin Irrit. 2 (100%)
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H302-H315-H319-H335
- Precautionary statements
- P261-P305+P351+P338
Chemistry & industry
Pharmacology
Pharmacodynamics
Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.
Mechanism of ActionOmapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
Metabolism/MetabolitesHepatic
MeSH Pharmacological Classification
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A class of cardiovascular drugs indicated for hypertension and congestive heart failure that simultaneously inhibit both NEUTRAL ENDOPEPTIDASE and ANGIOTENSIN CONVERTING ENZYME. They increase the availability of NATRIURETIC PEPTIDES and BRADYKININ and inhibit production of ANGIOTENSIN II.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Absorption, Distribution and ExcretionThe absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.
Applications
UsesTreatment of hypertension and congestive heart failure (neutral endopeptidase and angiotensin converting enzyme inhibitor).
Suppliers22 total
北京华美互利生物化工010-56205725 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
Aladdin Scientific[email protected]
InvivoChem中国13549236410 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
上海瀚香生物科技有限公司177-54423994 17754423994 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
青岛海智微元生物科技有限公司18317699790 18317699790 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
BOC Sciences16314854226; +8616314854226 · [email protected]
安耐吉化学&3A（安徽泽升科技股份有限公司）400-0056266 · [email protected]
上海一飞生物科技有限公司021-65675885 18964387627 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
范德(北京)生物科技有限责任公司15911056312 · [email protected]
SHANGHAI KEAN TECHNOLOGY CO., LTD.+8613817748580 · [email protected]
ChemeGen 中国18818260767 · [email protected]
HANGZHOU CLAP TECHNOLOGY CO.,LTD86-571-88216897,88216896 13588875226 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
InvivoChem+1-708-310-1919 +1-13798911105 · [email protected]
Additional notes
DefinitionChEBI: Omapatrilat is a dipeptide.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…